Reviewing Lucira Health (LHDX) and Its Competitors

Lucira Health (NASDAQ: LHDX) is one of 36 public companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare Lucira Health to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Valuation and Earnings

This table compares Lucira Health and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Lucira Health $270,000.00 -$37.35 million -0.36
Lucira Health Competitors $405.90 million $35.95 million -56.48

Lucira Health’s rivals have higher revenue and earnings than Lucira Health. Lucira Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

50.1% of Lucira Health shares are owned by institutional investors. Comparatively, 52.9% of shares of all “Diagnostic substances” companies are owned by institutional investors. 7.5% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Lucira Health and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lucira Health N/A N/A N/A
Lucira Health Competitors -3,099.44% -696.75% -183.84%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Lucira Health and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lucira Health 1 1 1 0 2.00
Lucira Health Competitors 179 664 1087 34 2.50

Lucira Health presently has a consensus price target of $9.00, suggesting a potential upside of 61.58%. As a group, “Diagnostic substances” companies have a potential downside of 0.13%. Given Lucira Health’s higher probable upside, equities research analysts clearly believe Lucira Health is more favorable than its rivals.

Summary

Lucira Health rivals beat Lucira Health on 7 of the 12 factors compared.

Lucira Health Company Profile

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.